e-learning
resources
ERJ
2006
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer
Dooms C. A., Lievens Y. N., Vansteenkiste J. F.
Source:
Eur Respir J 2006; 27: 895-901
Journal Issue:
May
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Dooms C. A., Lievens Y. N., Vansteenkiste J. F.. Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer. Eur Respir J 2006; 27: 895-901
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
A cost minimisation comparison of five chemotherapy regimes for advanced nonsmall cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 431s
Year: 2003
Treatment of advanced non-small cell lung cancer
Source: Annual Congress 2005 - PG2 - Lung cancer: non-small cell lung cancer treatment
Year: 2005
A study comparing the efficacy, quality of life and toxicity of cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer in the Indian scenario
Source: Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Year: 2011
Chemotherapy in advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 271–283
Year: 2009
Should patients with metastatic NSCLC and poor performance status be treated by chemotherapy?
Source: Annual Congress 2007 - Treatment of metastatic nonsmall cell lung cancer in the era of targeted therapies
Year: 2007
Neo-adjuvant chemotherapy: level of evidence in early stage and in marginally resectable disease
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Neoadjuvant and adjuvant treatment for operable nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 244–259
Year: 2009
Is there any place for perioperative radiation therapy?
Source: Annual Congress 2005 - Multidisciplinary treatment of non-metastatic non-small cell lung cancer: contemporary concepts
Year: 2005
Chemotherapy in nonsmall cell lung cancer
Source: ISSN=1025-448x, ISBN=1-904097-18-9, page=218
Year: 2001
Lung function evaluation in gemcitabine and concurrent radiotherapy treatment in nonsmall cell lung cancer (NSCLC)
Source: Eur Respir J 2001; 18: Suppl. 33, 376s
Year: 2001
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2012; 39: 172-179
Year: 2012
Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3
Source: Eur Respir J 2011; 39: 172-179
Year: 2012
The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer with interstitial lung disease.
Source: International Congress 2017 – Lung cancer: clinical research on exhaled breath, clinical trials in advanced NSCLC and real-life appraisals of immunotherapies
Year: 2017
Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives
Source: Eur Respir Rev 2011; 20: 45-52
Year: 2011
Histology as a potential clinical predictor of outcome in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine and mitomycin (VM) combination chemotherapy
Source: Annual Congress 2012 - Treatment of lung cancer
Year: 2012
Use of 2
nd
-line polychemotherapy in advanced nonsmall cell lung cancer – a reasonable approach
Source: Eur Respir J 2003; 22: Suppl. 45, 65s
Year: 2003
Role of chemotherapy in stage III non-small cell lung cancer (NSCLC): adjuvant or induction?
Source: Annual Congress 2006 - Integrative approaches for stage III non-small cell lung cancer
Year: 2006
Efficacy and safety of Pemetrexed (PEM) for elderly patients with advanced non-small cell lung cancer (NSCLC) who had previous chemotherapy
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010
The big lung trial (BLT): determining the value of cisplatin-based chemotherapy for all patients with non-small cell lung cancer (NSCLC). Preliminary results in the radical radiotherapy setting
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003
Impact of radiotherapy on outcomes of nivolumab in advanced non-small cell lung cancer: a case controlled study
Source: International Congress 2018 – Lung cancer: personalised medicine
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept